GLP-2 (T)
❄️Lyophilized powder
Size:
Discount per Quantity
| Quantity | Discount | Price per Unit |
|---|---|---|
| 5 - 10 | 10% | €89.10 |
| 11 - 20 | 15% | €84.15 |
| 21+ | 20% | €79.20 |
Rigorous third-party testing
Every batch of our research chemicals and peptides undergoes independent third-party laboratory testing for purity and identity.
Total: €99.00
For laboratory research use only by qualified professionals. Not for human or veterinary use. Not for ingestion, injection, topical application, diagnostic, therapeutic, prophylactic or cosmetic use.
GLP-2 (T) / Tirzepatide is supplied as a catalogued research material in 10mg, 20mg and 30mg. It is intended only for controlled analytical, biochemical and non-clinical laboratory workflows. The catalogue amount identifies the nominal vial presentation; it is not a dose or a use instruction.
“GLP-2 (T)” is a catalogue alias, not a chemical identity. Tirzepatide is a modified GIP-derived peptide and dual GIP/GLP-1 receptor agonist; GLP-2 is a different endogenous 33-residue hormone. Registry assignment requires confirmation of the complete modified structure and batch form [1–3].
Product identity
Identity must be assigned to the exact batch rather than to a marketed name alone. Sequence, terminal modifications, conjugation, salt or counter-ion, hydration state and excipients may change the applicable mass and registry identifiers. The batch CoA and SDS take precedence over literature identifiers shown below.
Chemical properties and registry information
| Property | Value |
|---|---|
| Name and synonyms | Tirzepatide; catalogue alias “GLP-2 (T)” only; not GLP-2 |
| Material category | Modified GIP-derived dual GIP/GLP-1 receptor agonist; prescription-medicine active substance; high-risk research material |
| Sequence or structural definition | Y–Aib–EGTFTSDYSI–Aib–LDKIAQK[acyl]–AFVQWLIAGGPSSGAPPPS–NH₂ (39-residue modified backbone) |
| Molecular formula | C225H348N48O68 for the defined tirzepatide parent structure; salts, counter-ions and solvates differ |
| Average molecular mass | 4813.53 g/mol average mass for the defined parent structure |
| CAS Registry Number | 2023788-19-2 for the defined tirzepatide structure, conditional on exact-form confirmation |
| PubChem CID | CID 156588324 for tirzepatide; use only after modified sequence, conjugate and exact-form confirmation |
| Structural features | Aib residues at positions 2 and 13, a linker/C20 fatty-diacid substituent on Lys20, and a C-terminal amide; exact conjugation and salt require batch confirmation |
| Physical form | Catalogue vial; the exact physical state, salt or counter-ion and excipients are batch-specific and must be verified in the CoA and SDS. |
| Catalogue presentations | 10mg, 20mg and 30mg |
| Batch identity and quality documentation | Lot-specific identity and available analytical reports must be verified against the CoA entry associated with the exact product size and batch. |
| Intended use | Analytical, biochemical and non-clinical laboratory research only; all human and veterinary uses are excluded. |
Where an identifier is qualified or omitted, no unambiguous exact-form public assignment has been confirmed. Do not transfer an identifier from a related analogue, salt, conjugate or formulation.
Research context and evidence status
What the literature supports
Defined tirzepatide reference material can support structural confirmation, impurity profiling, receptor-pharmacology research and analytical-method development. That research context requires exact modified-peptide identity and does not make a catalogue vial equivalent to a separately manufactured medicinal product [1,3].
Evidence limitations
Clinical evidence and authorization for branded tirzepatide medicines are formulation-, strength-, indication- and manufacturer-specific. They do not establish identity, purity, bioequivalence, safety, efficacy, dosage, administration or authorization for this catalogue material [3,4].
Tirzepatide is the active substance in the prescription medicine Mounjaro. A research-use label does not confer medicine authorization or permit unapproved human supply; FDA specifically warns about unapproved tirzepatide products and products falsely labelled “for research purposes.” Do not imply equivalence to Mounjaro or any authorised product [3,4].
| Important | Research-use labeling does not itself determine the substance-specific legal status. The purchaser is responsible for confirming institutional authorization, local restrictions and lawful procurement, possession, import, export, storage and disposal. |
Technical comparison
The comparison below is limited to structural and analytical distinctions. It does not compare clinical performance or recommend a use.
| Aspect | This catalogue material | Comparator |
|---|---|---|
| Identity | Tirzepatide, subject to confirmation of its complete modified structure and batch form | Native human GLP-2 peptide |
| Structural distinction | Modified 39-residue GIP-derived peptide with Aib residues and a lipid conjugate | Distinct endogenous 33-residue GLP-2 hormone without tirzepatide's structure |
| Analytical implication | Requires intact-mass, modified-sequence, conjugation-site, amidation, purity and assay controls | GLP-2 sequence, mass and registry data cannot identify tirzepatide |
| What is not implied | No conclusion about human or veterinary safety, efficacy, dosage, route, duration or interchangeability. | No conclusion about human or veterinary safety, efficacy, dosage, route, duration or interchangeability. |
Quality and batch documentation
Quality information is batch- and presentation-specific. Use only the report linked to the exact size and lot. A report listed for another size, lot or similarly named material must not be treated as evidence for this product.
Chromatographic area purity, identity, net peptide or analyte content, water or counter-ion content, sterility, endotoxin and elemental impurities are different measurements. One result does not establish the others. Only tests supported by a visible, matching report should be regarded as available.
Laboratory handling and storage
Store and handle only under the conditions stated on the product label, batch CoA and SDS. Keep the container secured, correctly identified and protected from contamination. Do not infer storage, solvent compatibility or stability from a related compound.
This page intentionally provides no reconstitution, administration or dosing instructions. Laboratory preparation, analytical method selection, risk assessment, personal protective equipment and waste disposal must be defined by the qualified institution and the applicable SDS.
Regulatory and legal status
This catalogue material is not offered as a medicine, medical device, in-vitro diagnostic, food, dietary supplement, cosmetic or veterinary product. It is not intended to diagnose, treat, cure, mitigate or prevent any disease or condition.
A research designation does not override medicinal-product, controlled-substance, chemical, customs or other substance-specific rules. Availability may be restricted by jurisdiction and by the purchaser's verified professional or institutional status.
Sources and references
References document identity and research context only. They do not constitute instructions for use or evidence that this catalogue batch is suitable for any human or veterinary purpose.
- [1] PubChem. Tirzepatide structure and registry record, CID 156588324.
- [2] IUPHAR/BPS Guide to Pharmacology. GLP-2 structure: distinct endogenous 33-residue peptide.
- [3] European Medicines Agency. Mounjaro: authorised prescription tirzepatide medicinal product.
- [4] U.S. FDA. Concerns with unapproved GLP-1 drugs, including false research-use labelling.
Frequently Asked Questions
What is this material intended for?
Controlled laboratory research by qualified professionals, including substantiated analytical, biochemical or non-clinical workflows. It is not intended for personal use.
Is the amount shown on the vial a dosage?
No. It is a nominal catalogue presentation used to identify the product variant. It is not a dose, concentration, administration schedule or preparation instruction.
Do the CAS number and PubChem CID apply to every batch form?
Only when the exact sequence or structure, termini, conjugation, salt or counter-ion and hydration state match. The batch CoA and SDS govern; a related-compound identifier must not be substituted.
What does an analytical purity result mean?
It is method- and report-specific. For example, an HPLC area percentage is not automatically the same as identity, net content, sterility, endotoxin status or absence of elemental impurities.
How should the material be stored and handled?
Follow the exact label, batch CoA and SDS, together with the institution's risk assessment. This page does not provide reconstitution or administration guidance.
May this material be used in humans or animals?
No. Human and veterinary use, including ingestion, injection, topical application, diagnosis, treatment, prevention and cosmetic use, is expressly excluded.
RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. THE PRODUCT NAME, VIAL AMOUNT AND LITERATURE REFERENCES MUST NOT BE INTERPRETED AS A DOSAGE, ADMINISTRATION INSTRUCTION OR MEDICAL CLAIM.
LABORATORY REAGENT – FOR RESEARCH PURPOSES ONLY
This product is not a drug or food and should be handled by qualified professionals in laboratory conditions. All product information is provided for educational purposes only.
Information:
- The product (substance) isn't a food or diet supplement and is not suitable for human consumption.
- Keep out of children's reach
- Keep container tightly closed.
- Store in a dry, cool and shaded place; protect from moisture.
- Store only in the original container.
- Avoid contact during pregnancy and breast feeding.
- Consult a doctor in the event of feeling unwell or having adverse effects related to the contact with the substance.